A study exploring adjuvant capecitabine in early-stage TNBC failed but researchers are performing genomic analysis on a subset of patients who benefited.
Following promising data from its Circulating Cell-free Genome Atlas study, the firm decided to pivot its breast cancer trial to support its multi-cancer test.
The planned product, which will target drug-development companies, uses machine learning techniques to predict the outcomes and likelihood of success of clinical trials.
In this arm of the trial, 23 percent of patients treated with AKT1 E17K mutations saw their tumors shrink, a better result than those seen in three other trial arms.
NX Prenatal and Indiana University School of Medicine are collaborating to develop exosome blood tests for preterm birth risk and preeclampsia.
The prospective, multi-site clinical trial will evaluate the clinical utility of unbiased sequencing for identifying pathogens in suspected CNS infections.
Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.
The clinical trial matching app, which Roche collaborated on with MolecularMatch, is the latest in a series of features that it will introduce in its tumor board solution.
ScienceInsider reports that universities may be worse than drug companies at reporting clinical trial results.
The Associated Press reports on early, potentially promising results from a gene-editing trial.
An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.
An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.
In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.
Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.